Antineoplastic and Immunosuppressive Agents - Part II

Over the past two decades a number of attempts have been made, with varying degrees of success, to collect in a single treatise available information on the basic and applied pharmacology and biochemical mechanism of action of antineoplastic and immunosuppressive agents.

The logarithmic growth of knowledge in this field has made it progressively more difficult to do justice to all aspects of this topic, and it is possible that the present handbook, more than four years in preparation, may be the last attempt to survey in a single volume the entire field of drugs employed in cancer chemotherapy and immunosuppression.

Even in the present instance, it has proved necessary for practical reasons to publish the material in two parts, although the plan of the work constitutes, at least in the editors' view, a single integrated treatment of this research area.

A number of factors have contributed to the continuous expansion of research in the areas of cancer chemotherapy and immunosuppression.

Active compounds have been emerging at ever-increasing rates from experimental tumor screening systems maintained by a variety of private and governmental laboratories through- out the world. At the molecular level, knowledge of the modes of action of established agents has continued to expand, and has permitted rational drug design to play a significantly greater role in a process which, in its early years, depended almost completely upon empirical and fortuitous observations.